“MFS’ unique
solution reduces costs, increases reliability and produces
timely results.”
MicroFluidic Systems (MFS) - Making a Difference
in the Nation’s Ability to Mitigate Threats from
Biological Pathogens
The company’s key personnel have been involved
with technology development for biological pathogen
detection for over 15 years. MFS, as a company since
it’s inception in 2001, has had a key role in
developing technologies to automate the process of
biological pathogen detection. First, along with Lawrence
Livermore National Laboratory, MFS began developing
complex microfluidic systems to perform sample processing
and purification for the Defense Advanced Research Projects Agency (DARPA).
It then developed a similar system,
including a thermal cycler for PCR analysis for the
US Army’s Edgewood Chemical and Biological Command
(ECBC). In 2003, MFS secured several contracts with
the Department
of Homeland Security’s Science and Technology
Directorate for continuing its technology development
for autonomous air-borne pathogen detection. MFS is
currently one of a few prime contractors selected by
the Department of Homeland Security to develop the
next generation autonomous, air-borne pathogen detection
systems under two on-going contracts.
MFS is a wholly owned subsidiary of PositiveID Corporation. For more information, please visit www.PositiveIDCorp.com.
|
